Skip to main content

FLUCELVAX QUAD (Seqirus Pty Ltd)

Product name
FLUCELVAX QUAD
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
198 working days (255)
Active ingredients
influenza virus haemagglutinin
Registration type
NCE/NBE
Indication

FLUCELVAX QUAD (suspension for injection) is indicated for the prevention of influenza caused by Influenza Virus, Types A and B contained in the vaccine. The vaccine is indicated for use in adults and children 9 years of age and older.

For full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Help us improve the Therapeutic Goods Administration site